Alexander Spira, MD, PhD, Discusses Approval of Agents to Treated NSCLC With Exon 20 Insertion Mutations

Video

CancerNetwork® sat down with Alexander Spira, MD, PhD, FACP, at the 2021 World Conference on Lung Cancer to talk about future indications of mobocertinib.

At the 2021 World Conference on Lung Cancer, CancerNetwork® spoke with Alexander Spira, MD, PhD, FACP, of Virginia Cancer Specialists, about how an FDA approval of mobocertinib [TAK-788] could positivity impact patients with non–small cell lung cancer harboring EGFR exon 20 insertion mutations. 

Transcript:

Right now, there are no future trials looking at [mobocertinib in patients previously treated with EGFR inhibitor] specifically. In the United States, we have an approved drug amivantamab [Rybrevant] for [EGFR] exon 20 insertion–mutant non-small cell lung cancer, which is a very different approach. It’s a monoclonal antibody versus mobocertinib, and the others described, which are small molecule TKIs. What we’ll all be interested to see is if you give mobocertinib first and they respond to amivantamab, or if you give amivantimab first, will they respond to mobocertinib. So [providers] think that’s where the field is going right now. In terms of TKIs, it’s likely that we will see mobocertinib approved in the short term—or at least, we hope we will in the United States—giving us that armamentarium. Whether the other TKIs play in at this point remains to be seen.

Related Videos
A panel of 4 experts on lung cancer
A panel of 4 experts on lung cancer
Tailoring neoadjuvant therapy regimens for patients with mismatch repair deficient gastroesophageal cancer represents a future step in terms of research.
Not much is currently known about the factors that may predict pathologic responses to neoadjuvant immunotherapy in this population, says Adrienne Bruce Shannon, MD.
Data highlight that patients who are in Black and poor majority areas are less likely to receive liver ablation or colorectal liver metastasis in surgical cancer care.
Findings highlight how systemic issues may impact disparities in outcomes following surgery for patients with cancer, according to Muhammad Talha Waheed, MD.
Pegulicianine-guided breast cancer surgery may allow practices to de-escalate subsequent radiotherapy, says Barbara Smith, MD, PhD.
Adrienne Bruce Shannon, MD, discussed ways to improve treatment and surgical outcomes for patients with dMMR gastroesophageal cancer.
Barbara Smith, MD, PhD, spoke about the potential use of pegulicianine-guided breast cancer surgery based on reports from the phase 3 INSITE trial.
Patient-reported symptoms following surgery appear to improve with the use of perioperative telemonitoring, says Kelly M. Mahuron, MD.
Related Content